Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) EBT Margin (2018 - 2025)

Historic EBT Margin for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to 28.76%.

  • Dna X's EBT Margin fell 128200.0% to 28.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.03%, marking a year-over-year decrease of 348500.0%. This contributed to the annual value of 58.42% for FY2024, which is 591800.0% down from last year.
  • Latest data reveals that Dna X reported EBT Margin of 28.76% as of Q3 2025, which was down 128200.0% from 65.56% recorded in Q2 2025.
  • In the past 5 years, Dna X's EBT Margin ranged from a high of 3.53% in Q1 2025 and a low of 148.85% during Q4 2024
  • Moreover, its 5-year median value for EBT Margin was 28.76% (2025), whereas its average is 37.37%.
  • In the last 5 years, Dna X's EBT Margin soared by 695700bps in 2022 and then plummeted by -1426300bps in 2024.
  • Dna X's EBT Margin (Quarter) stood at 73.96% in 2021, then surged by 94bps to 4.39% in 2022, then plummeted by -42bps to 6.22% in 2023, then crashed by -2294bps to 148.85% in 2024, then surged by 81bps to 28.76% in 2025.
  • Its EBT Margin was 28.76% in Q3 2025, compared to 65.56% in Q2 2025 and 3.53% in Q1 2025.